Skip to content
TrialScanner

NCT01899859

Phase 1 Study to Evaluate Safety of GR-MD-02 in Subjects With Non-Alcoholic Steatohepatitis (NASH) and Advanced Fibrosis

Phase 1CompletedGALTLead

Registry record

Lead sponsor
Galectin Therapeutics Inc.
Conditions
Non-Alcoholic Steatohepatitis (NASH)
Primary completion
Feb 2015Actual
Completion
Locked
Start
Locked
Enrollment
Locked
Interventions
Locked
Study type
Locked
Results on the registry
Locked
Record last updated
Locked

Open NCT01899859 on ClinicalTrials.gov

Enrollment, interventions, the start and completion dates and the change history are locked on 1 row here. Included with TrialScanner ($9.99 a month) and Signal8 Pro.

Unlock with TrialScanner

Recorded changes

0 changes recorded for this trial. The history, with each previous value, is part of TrialScanner.

Tracking since Nov 12, 2026. Changes before that date are not known to TrialScanner.

    NCT01899859: Phase 1 Study to Evaluate... | TrialScanner